Boulder-based Biodesix raises another $5.1 million

BOULDER — Local diagnostic test-maker Biodesix Inc. has pulled in another new chunk of funding as the company continues to grow its Veristrat and other products.

According to a regulatory filing made this week, the company has raised about $5.1 million through the issuance of new convertible notes. The filing noted a total offering of $15.7 million, meaning more cash could be on the way.

Biodesix CEO David Brunel couldn’t be reached for comment Friday.

Biodesix, which is headquartered at 2970 Wilderness Place, makes a line of blood tests that are focused on identifying which…